ibrous tissue accumulation is a feature of the structural remodeling of the myocardium seen in hypertensive heart disease.1 An exaggerated accumulation of collagen type I and type III occurs in the hypertrophied myocardium and also in the nonhypertrophied right ventricle and in the atria of animals and humans with arterial hypertension. This collagen accumulation has adverse effects. It results in the develop ment of increased myocardial stiffness that leads to diastolic dysfunction and ultimately to the development of systolic dysfunction.
F ibrous tissue accumulation is a feature of the structural remodeling of the myocardium seen in hypertensive heart disease.1 An exaggerated accumulation of collagen type I and type III occurs in the hypertrophied myocardium and also in the nonhypertrophied right ventricle and in the atria of animals and humans with arterial hypertension. This collagen accumulation has adverse effects. It results in the develop ment of increased myocardial stiffness that leads to diastolic dysfunction and ultimately to the development of systolic dysfunction.
Recently, a new therapeutic strategy against hypertrophy has emerged from the use of Na^/H^ exchanger (NHE) inhibitors.2-5 The inhibition of NHE-1 reduces the hypertro phy of the surviving myocytes after myocardial infarction3 and of the hearts of spontaneously hypertensive rats (SHR)2 and mice overexpressing ^1-adrenergic receptors. 4 Taken together, these findings seem to indicate a key role of NHE activity in the development of myocardial hypertrophy. Even though our recent study showed that neither myocardial fibrosis nor stiffness was normalized in the SHR after 1 month of cariporide treatment,2 the regression of fibrosis was observed after 6 months of NHE inhibition in another model of cardiac hypertrophy, the transgenic mice overexpressing ^1-adrenergic receptors. 4 Considering that the regression of myocyte hypertrophy and collagen accumulation might have different time course, the present study sought to determine whether a more prolonged treatment with the NHE-1 blocker would cause a reduction in myocardial fibrosis in the SHR model of cardiac hypertrophy. A possible link between NHE-1 activity and fibrosis may rely on the fact that the antiporter is a downstream effector of several fibrosis-related signaling systems such as transforming growth factor-^ (TGF^) and the renin-angiotensin-aldosterone system.6-8
Methods
Experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals (NIH publication No 85-23, revised 1996) with 50 male SHR and 31 normotensive Wistar (NT) rats (4 months old). At this age and after recording baseline body weight (BW) and systolic blood pressure (SBP) by the tail-cuff method,2 the rats were assigned to either (a) death, to assess baseline cardiac parameters; (b) no drug treatment or; (c) cariporide treatment (3.0 mg/kg per day). Baseline BW in SHR was lower than in NT10 (mean values were 296^8 and 246^5g in NT and SHR, respective ly). There was no difference in BW gain during the experiment; BW reached 367^7, 323^9, and 325^10 g in NT, SHR, and cariporidetreated SHR 3 months later, respectively. Animals were euthanized after 1, 2, or 3 months of treatment under ether anesthesia, and their
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February 2003 Myocardial stiffness was determined in LV papillary muscles as previously described.2 Briefly, the muscles were stretched stepwise until the twitch-developed force reached the maximum. At each step, the muscle length was increased by 10% of the muscle length at zero resting tension (L0). The stress-strain relation of each muscle was fitted to an exponential equation of the form ^^A^eK^, where K represents the elastic stiffness constant. From each fitting, the stress values at given values of strain were estimated by interpolation and plotted as a function of strain.
Although circulating cariporide levels were not determined in our study, it was shown that rats treated with a similar or even lower dosage than ours had cariporide plasma levels higher than that required to inhibit NHE-1 activity by 50% in isolated cardiomyocytes.11 More importantly, our previous report demonstrated that doses of 0.3 mg/kg per day and 3.0 mg/kg per day induced antihypertrophic effects in SHR. 2 Ventricular tissue was fixed in buffered 10% formaldehyde and paraffin-embedded. LV coronal sections (5 ^m thick) at the equator were stained for determining cardiomyocyte cross-sectional area (CSA) and quantifying collagen volume fraction (CVF) as previ ously described.2 To assess CSA, only round to ovoid cells with visible round nucleus were considered, and 50 cells were counted in at least 10 images obtained from each LV. CVF was calculated as the sum of all connective tissue areas divided by the total section surface, in no less than 10 images. Perivascular collagen was excluded from this measurement.
Serum levels of the carboxyterminal propeptide of procollagen type I (PIP), a marker of collagen type I synthesis, were determined as previously described by radioimmunoassay with a commercial assay kit (Orion Diagnostica).2,9 The lower detection limit (method sensitivity) was 1.2 ^g/L.
Statistics
Data are presented as mean^SEM. The K values of the exponential fitting of the stress-strain relation were used to compare stiffness in the papillary muscles. One-way ANOVA followed by the StudentNewman-Keuls post hoc test was used to assess differences between groups. The ANCOVA analysis was also applied to analyze the effect of NHE-1 inhibition on LVW, using the initial BW as the covariate. The significance level was set at P^0.05.
Results
The SHR used in this study had, at the beginning of the experiment, established hypertension with cardiac hypertro phy and fibrosis. The Table shows values of the variables studied at baseline and different time points during the experimental protocol. After 1 month, cariporide produced a slight decrease of SBP that was previously reported by us.2 This decrease was sustained until the end of the treatment (3 months), when SBP was ^ 5 mm Hg lower compared with baseline and untreated age-matched SHR.
Cariporide treatment attenuated cardiac hypertrophy in SHR, as shown in the Table. After 3 months of treatment, LVW in treated SHR was significantly lower compared with LVW in age-matched untreated SHR. To avoid the influence of the lighter BW of SHR on the appearance of the antihypertrophic effect, the LVW was normalized by BW (Table) . LVW/BW ratio remained slightly elevated in cariporidetreated SHR compared with NT, although the difference did not reach the level of significance. In addition, an analysis of covariance using the starting BW as the covariate was applied to further address the possibility that the lighter initial BW of SHR would have affected the results. The analysis showed a statistical, highly significant difference (P^0.0001) between the adjusted LVW means, implying that there was not an overestimation of the antihypertrophic effect of NHE inhibi tion caused by the lighter BW of SHR.
The increased CSA of cardiomyocytes returned to a value within the normal range after 1 month of cariporide treatment ( Figure 1A) , and their size remained stable throughout the rest of the treatment. The normalization of cardiomyocyte size after 1 month of NHE-1 inhibition as well as the lack of effect on myocardial fibrosis at this time point ( Figure 1B) were previously reported by us.2 Left ventricular collagen volume fraction (LVCVF) in untreated SHR was increased compared with age-matched NT at any time point during the treatment (Table) . NHE-1 inhibition for 2 to 3 months induced a decline in myocardial fibrosis (not detected after 1 month), so that LVCVF reached values not different from those found in age-matched NT rats ( Figure 1B and the  Table) . The changes in serum PIP paralleled the changes in myocardial fibrosis: PIP levels were significantly elevated in untreated SHR compared with NT rats and returned to normal values after 2 or 3 months of cariporide treatment ( Figure 1C) . Figure 2 shows representative images of the increased interstitial fibrosis seen in LV of SHR and the progressive involution to normal content induced by 2 and 3 months of cariporide treatment.
Muscles from hypertensive hypertrophied hearts were stiffer than those from NT, as denoted by the leftward shift of the length-tension curves shown in Figure 3A . Myocardial stiffness was restored to normal after 2 or 3 months of cariporide treatment (Figures 3B and 3C ). Considered as a whole, the data presented herein would indicate that treatment with an NHE-1 inhibitor should last for more than 1 month to interfere with collagen synthesis, normalize myocardial col lagen content, and restore myocardial distensibility in SHR.
Discussion
Our results demonstrate the ability of the NHE-1 inhibitor cariporide to regress cardiac fibrosis in SHR with established hypertension. The decrease in fibrous tissue was accompa nied by a decrease in the serologic marker of collagen type I synthesis, PIP. Of importance, the regression of fibrosis occurred in the absence of (or minimal) reduction in arterial pressure, indicating the hemodynamic independence of the mechanism. According to the regression in collagen content, a major determinant of tissue stiffness, there was an improve ment in myocardial distensibility. Even though this is the first demonstration of the regression of myocardial fibrosis in the hypertensive heart induced by NHE-1 inhibition, an effect of cariporide on the fibrotic hypertrophied heart of mice over expressing ^1 receptors has been recently reported.4 A recent study from our laboratory reported that 1 month of cariporide treatment induced the regression of cardiomyo Figure 1 . Effect of NHE-1 inhibition on LV cardiomyocyte CSA (A), collagen volume fraction (B), and serum PIP levels (C). Untreated NT rats (open bar, n^4), untreated SHR (closed bar), and cariporide-treated SHR were studied for 1, 2, or 3 months (hatched bars, n^4 each). For the sake of clarity and since there was no significant difference between the untreated SHR for 1, 2, or 3 months, all data were pooled into one group, n^12. *P^0.05 vs other groups, 1-way ANOVA.
cyte hypertrophy in SHR without a detectable effect on fibrosis, myocardial stiffness, or serum PIP levels.2 The present study shows that extending cariporide treatment results in complete regression of myocardial fibrosis associ ated with the normalization of myocardial distensibility and serum PIP concentration. It has been recognized before that myocyte size declines, with antihypertensive therapy, more rapidly than the amount of collagen, a stable protein with 80 to 120 days half-life in myocardium. 12 Signaling pathways leading to myocardial fibrosis are complex, yet incompletely defined. Diastolic dysfunction accompanies those models of cardiac hypertrophy in which myocardial fibrosis is also present,13 but no sign of diastolic dysfunction has been reported in cardiac hypertrophy when fibrosis is absent.14 -16 Our results show that the regression of cardiomyocyte hypertrophy is not enough to normalize myo cardial distensibility. The restoration of normal distensibility accompanied the decline in the amount of collagen, suggest ing that fibrosis and not muscle mass per se is the major determinant of diastolic stiffness in the hypertrophied heart of SHR. In connection with this, the study of Brilla et al17 showed that the reduction of collagen content and the improvement of diastolic dysfunction in hypertensive patients were independent of the regression of cardiomyocyte hyper trophy. Regression of myocardial fibrosis and improvement of diastolic distensibility after long-term interruption of the renin-angiotensin system were previously reported in both SHR and hypertensive humans. [17] [18] [19] It has been proposed that myocardial stiffness is a function of cross-linked collagen.20 Whether NHE-1 inhibition de creased cross-linked collagen was not explored in this study, but the normalization of myocardial distensibility after cariporide treatment may suggest an effect on insoluble collagen.
In our experiments we cannot exclude that changes in collagen degradation after NHE-1 blockade could have con- tributed to the involution of cardiac fibrosis. However, Diez et al19,21 have shown that fibrosis correlates best with the serologic marker of collagen type I synthesis.
Fibroblasts play the main role in fibrinogenesis; several growth factors including the TGF^ and the circulating and tissue components of the renin-angiotensin-aldosterone sys tem are potent activators of collagen synthesis in (myo)fibroblasts.12,22 TGF^1 binds to membrane receptors and transmits signals via mitogen-activated protein kinases (MAPK)-dependent and Smad-dependent pathways. 23 In postinfarcted myocardium, a condition in which NHE-1 inhibition proved to be beneficial,3 Smad expression is elevated and normalized after Angiotensin II AT1 blockade.24,25 NHE-1 is a common downstream effector of various of these intracellular signal ing mechanisms.6,7 It was reported by Takewaki et al26 that the inhibition of NHE-1 activity partially decreased the activation of MAPK and protein synthesis elicited by stretch.
Several still unanswered questions have arisen from the findings presented herein. How does NHE-1 inhibition reduce myocardial hypertrophy? Is the decrease in Na^ influx due to NHE-1 blockade the main mechanism? It should be kept in mind that the amount of Na^ entering through NHE-1 accounts for approximately half the total Na^ influx.27 A link between Na^ influx by NHE and the activation of PKC-^ and PKC-^ isoforms in response to growth factors has been reported in isolated cardiomyocytes.28 ^he intracellular Na^ is elevated in hypertrophied myocardium,29 and Na^ has a direct effect on protein synthesis increase and on protein degradation decrease.30 Epidemiological and basic studies support the notion that Na^ is an independent factor for the development of myocardial hypertrophy.31,32 Frohlich and colleagues33 reported that a high Na^ diet increased not only cardiac enlargement in SHR but also cardiac mass in normotensive rats without detectable change of arterial pressure.
Perspectives
Clinical and epidemiological studies indicate that diastolic heart failure is mainly caused by hypertensive heart disease. It is now well recognized that it is not only the quantity but also the quality of the myocardium that is responsible for adverse cardiovascular effects in hypertensive heart disease. Increased fibrous tissue predisposes to an increased risk for diastolic and/or systolic dysfunction and, ultimately, to heart failure. Our findings that NHE-1 inhibition induces the normalization of myocardial distensibility and fibrosiseffects associated with a normalization of increased collagen synthesis-may be of particular importance for the treatment of hypertensive patients.
